Skip to main content

Advertisement

SpringerLink
Log in

KCNJ1 inhibits tumor proliferation and metastasis and is a prognostic factor in clear cell renal cell carcinoma

  • Research Article
  • Published:
Tumor Biology

Abstract

Potassium inwardly rectifying channel, subfamily J, member 1 (KCNJ1), as an ATP-dependent potassium channel, plays an essential role in potassium balance. KCNJ1 variation is associated with multiple diseases, such as antenatal Bartter syndrome and diabetes. However, the role of KCNJ1 in clear cell renal cell carcinoma (ccRCC) is still unknown. Here, we studied the expression and function of KCNJ1 in ccRCC. The expression of KCNJ1 was evaluated in ccRCC tissues and cell lines by quantitative real-time PCR (qRT-PCR), Western blot, and immunohistochemistry analysis. The relationship between KCNJ1 expression and clinicopathological characteristics was analyzed. p3xFLAG-CMV-14 vector containing KCNJ1 was constructed and used for transfecting ccRCC cell lines 786-O and Caki-2. The effects of KCNJ1 on cell proliferation, invasion, and apoptosis were detected in ccRCC cell lines using cell proliferation assay, transwell assay, and flow cytometry, respectively. We found that KCNJ1 was low-expressed in ccRCC tissues samples and cell lines, and its expression level was significantly associated with tumor pathology grade (P = 0.002) and clinical stage (P = 0.023). Furthermore, the KCNJ1 expression was a prognostic factor of ccRCC patient’s survival (P = 0.033). The re-expression of KCNJ1 in 786-O and Caki-2 significantly inhibited cancer cell growth and invasion and promoted cancer cell apoptosis. Moreover, knockdown of KCNJ1 in HK-2 cells promoted cell proliferation. Collectively, these data highlight that KCNJ1, low-expressed in ccRCC and associated with poor prognosis, plays an important role in ccRCC cell growth and metastasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Vasudev NS, Selby PJ, Banks RE. Renal cancer biomarkers: the promise of personalized care. BMC Med. 2012;10:112.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.

    Article  PubMed  Google Scholar 

  3. Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006;49:798–805.

    Article  PubMed  Google Scholar 

  4. Patil S, Manola J, Elson P, Negrier S, Escudier B, Eisen T, et al. Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trials. J Urol. 2012;188:2095–100.

    Article  PubMed  Google Scholar 

  5. He GC, Wang HR, Huang SK, Huang CL. Intersectin links WNK kinases to endocytosis of ROMK1. J Clin Investig. 2007;117:1078–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Hebert SC, Desir G, Giebisch G, Wang W. Molecular diversity and regulation of renal potassium channels. Physiol Rev. 2005;85:319–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Foster DB, Ho AS, Rucker J, Garlid AO, Chen L, Sidor A, et al. Mitochondrial ROMK channel is a molecular component of mitoK(ATP). Circ Res. 2012;111:446–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. O’Connell AD, Leng Q, Dong K, MacGregor GG, Giebisch G, Hebert SC. Phosphorylation-regulated endoplasmic reticulum retention signal in the renal outer-medullary K+ channel (ROMK). Proc Natl Acad Sci U S A. 2005;102:9954–9.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Yue P, Lin DH, Pan CY, Leng Q, Giebisch G, Lifton RP, et al. Src family protein tyrosine kinase (PTK) modulates the effect of SGK1 and WNK4 on ROMK channels. Proc Natl Acad Sci U S A. 2009;106:15061–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Lin D, Sterling H, Lerea KM, Giebisch G, Wang WH. Protein kinase c (PKC)-induced phosphorylation of ROMK1 is essential for the surface expression of ROMK1 channels. J Biol Chem. 2002;277:44278–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Yoo D, Kim BY, Campo C, Nance L, King A, Maouyo D, et al. Cell surface expression of the ROMK (Kir 1.1) channel is regulated by the aldosterone-induced kinase, SGK-1, and protein kinase a. J Biol Chem. 2003;278:23066–75.

    Article  CAS  PubMed  Google Scholar 

  12. Srivastava S, Li D, Edwards N, Hynes AM, Wood K, Al-Hamed M, et al. Identification of compound heterozygous KCNJ1 mutations (encoding ROMK) in a kindred with Bartter’s syndrome and a functional analysis of their pathogenicity. Physiol Rep. 2013;1:e00160.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Huang L, Luiken GPM, van Riemsdijk IC, Petrij F, Zandbergen AAM, Dees A. Nephrocalcinosis as adult presentation of Bartter syndrome type II. Neth J Med. 2014;72:91–3.

    CAS  PubMed  Google Scholar 

  14. Cho JT, Guay-Woodford LM. Heterozygous mutations of the gene for Kir 1.1 (ROMK) in antenatal Bartter syndrome presenting with transient hyperkalemia, evolving to a benign course. J Korean Med Sci. 2003;18:65–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Fretzayas A, Gole E, Attilakos A, Daskalaki A, Nicolaidou P, Papadopoulou A. Expanding the spectrum of genetic mutations in antenatal Bartter syndrome type II. Pediatr Int. 2013;55:371–3.

    Article  CAS  PubMed  Google Scholar 

  16. Karnes JH, McDonough CW, Gong Y, Vo TT, Langaee TY, Chapman AB, et al. Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment. Pharmacogenomic J. 2013;13:430–6.

    Article  CAS  Google Scholar 

  17. Zhou X, Zhang Z, Shin MK, Horwitz SB, Levorse JM, Zhu L, et al. Heterozygous disruption of renal outer medullary potassium channel in rats is associated with reduced blood pressure. Hypertension. 2013;62:288–94.

    Article  CAS  PubMed  Google Scholar 

  18. Zhu X, Liang J, Shrubsole MJ, Ness RM, Cai Q, Long J, Chen Z, Li G, Wiese D, Zhang B, Smalley WE, Edwards TL, Giovannucci E, Zheng W, Dai Q. Calcium intake and ion transporter genetic polymorphisms interact in human colorectal neoplasia risk in a 2-phase study. J Nutr. 2014; [Epub ahead of print] doi:10.3945/jn.114.196709.

  19. Valletti A, Gigante M, Palumbo O, Carella M, Divella C, Sbisa E, et al. Genome-wide analysis of differentially expressed genes and splicing isoforms in clear cell renal cell carcinoma. PLoS One. 2013;8:e78452.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Wahafu W, He ZS, Zhang XY, Zhang CJ, Yao K, Hao H, et al. The nucleosome binding protein nsbp1 is highly expressed in human bladder cancer and promotes the proliferation and invasion of bladder cancer cells. Tumour Biol. 2011;32:931–9.

    Article  CAS  PubMed  Google Scholar 

  21. Gamba G, Friedman PA. Thick ascending limb: The Na(+):K (+):2Cl (−) co-transporter, NKCC2, and the calcium-sensing receptor, CaSR. Pflug Arch Eur J Phys. 2009;458:61–76.

    Article  CAS  Google Scholar 

  22. Sahmoun AE, Singh BB. Does a higher ratio of serum calcium to magnesium increase the risk for postmenopausal breast cancer? Med Hypotheses. 2010;75:315–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Cheng MH, Chiu HF, Tsai SS, Chen CC, Yang CY. Calcium and magnesium in drinking-water and risk of death from lung cancer in women. Magnes Res. 2012;25:112–9.

    CAS  PubMed  Google Scholar 

  24. Dai Q, Motley SS, Smith Jr JA, Concepcion R, Barocas D, Byerly S, et al. Blood magnesium, and the interaction with calcium, on the risk of high-grade prostate cancer. PLoS One. 2011;6:e18237.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This project was supported by grants from the National Natural Science Foundation of China (No. 81372746).

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Urology, Peking University First Hospital, No. 8, Xishiku Street, Xicheng District, Beijing, 100034, China

    Zhongqiang Guo, Jin Liu, Lian Zhang, Boxing Su, Yunchao Xing, Qun He, Xuesong Li & Liqun Zhou

  2. The Institute of Urology, Peking University, No. 8, Xishiku Street, Xicheng District, Beijing, 100034, China

    Zhongqiang Guo, Jin Liu, Lian Zhang, Boxing Su, Yunchao Xing, Qun He, Xuesong Li & Liqun Zhou

  3. National Urological Cancer Center, Beijing, 100034, China

    Zhongqiang Guo, Jin Liu, Lian Zhang, Boxing Su, Yunchao Xing, Qun He, Xuesong Li & Liqun Zhou

  4. Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, 100101, China

    Weimin Ci

Authors
  1. Zhongqiang Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jin Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lian Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Boxing Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yunchao Xing
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Qun He
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Weimin Ci
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xuesong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Liqun Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Xuesong Li or Liqun Zhou.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guo, Z., Liu, J., Zhang, L. et al. KCNJ1 inhibits tumor proliferation and metastasis and is a prognostic factor in clear cell renal cell carcinoma. Tumor Biol. 36, 1251–1259 (2015). https://doi.org/10.1007/s13277-014-2746-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2746-7

Keywords

Search

Navigation